The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being
Abstract
BACKGROUND: Cannabis varies considerably in levels of its two major constituent cannabinoids - (delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). Recently, we found evidence that those who smoked cannabis containing detectable levels of CBD had fewer psychotic-like symptoms than those whose cannabis had no CBD. The present study aimed, first, to replicate those findings and, second, to determine whether protective effects of CBD may extend to other harms of cannabis, such as memory impairment and reduced psychological well-being. METHOD: A total of 120 current cannabis smokers, 66 daily users and 54 recreational users were classified into groups according to whether analysis of their hair revealed the presence or absence of CBD and high versus low levels of THC. All were assessed on measures of psychosis-like symptoms, memory (prose recall; source memory) and depression/anxiety. RESULTS: Lower psychosis-like symptoms were found in those whose hair had CBD compared with those without. However, this was seen only in recreational users, who had higher levels of THC in their hair. Higher THC levels in hair were associated with increased depression and anxiety. Prose recall and source memory were poorer in daily users with high THC levels in hair while recognition memory was better in individuals with CBD present in hair. CONCLUSIONS: CBD attenuates the psychotic-like effects of cannabis over time in recreational users. Higher THC negatively impacts on memory and psychological well-being. These findings raise concerns for the harms stemming from use of varieties such as 'skunk' (sensimillia), which lack any CBD but currently dominate the supply of cannabis in many countries.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A number of studies indicate that cannabis strains containing higher THC:CBD ratios may result in greater risk of psychotic outcomes, and that CBD might have anti-psychotic properties (27)(28)(29)47).”
From Association Between Cannabis and Psychosis: Epidemiologic Evidence (2016) · cites this paper as [28]
In the citing paper
“These findings are consistent with the observation that marijuana users of samples containing higher CBD concentrations in addition to Δ9-THC are less likely to experience psychotic symptoms than those who smoke samples without CBD (87).”
From Translational investigation of the therapeutic potential of Cannabidiol (CBD): Toward a new age (2018) · cites this paper as [87]
Citations
Cites
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients
Beck, A. T., Steer, R. A., Ball, R., & Ranieri, W. F. (1996) · Journal of Personality Assessment · doi:10.1207/s15327752jpa6703_13 · Cited by 5,965
Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review.
Moore, T. H., Zammit, S., Lingford-Hughes, A., Barnes, T. R., Jones, P. B., Burke, M., & Lewis, G. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61162-3 · Cited by 2,224
The SPQ: A Scale for the Assessment of Schizotypal Personality Based on DSM-III-R Criteria
Raine, A. (1991) · Schizophrenia Bulletin · doi:10.1093/schbul/17.4.555 · Cited by 2,164
Pertwee, R. G. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707442 · Cited by 2,047
D'Souza, D. C., Perry, E., MacDougall, L., Ammerman, Y., Cooper, T., Wu, Y.-T., Braley, G., Gueorguieva, R., & Krystal, J. H. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300496 · Cited by 1,024
Rivermead Behavioural Memory Test
la Cour, P., & GALLAGHER, K. (1990) · Nordisk Psykologi · doi:10.1080/00291463.1990.10636996 · Cited by 992
The GABAergic deficit hypothesis of major depressive disorder
Luscher, B., Shen, Q., & Sahir, N. (2011) · Molecular Psychiatry · doi:10.1038/mp.2010.120 · Cited by 934
Bergamaschi, M. M., Queiroz, R. H. C., Chagas, M. H. N., de Oliveira, D. C. G., De Martinis, B. S., Kapczinski, F., Quevedo, J., Roesler, R., Schröder, N., Nardi, A. E., et al. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.6 · Cited by 771 · cited 1×
“In contrast, cannabidiol (CBD), another major constituent of most strains of cannabis, may have anti-psychotic properties (Zuardi et al. 2006), is anxiolytic (Guimares et al. 1990 ; Bergamaschi et al. 2011) andmay be neuroprotective in humans (Hermann et al. 2007).”
BackgroundTraining and quality assurance with the Brief Psychiatric Rating Scale: "The drift busters."
Ventura, J., Green, M. F., Shaner, A. L., & Liberman, R. P. (1993) · International Journal of Methods in Psychiatric Research · Cited by 748
Bhattacharyya, S., Morrison, P. D., Fusar-Poli, P., Martin-Santos, R., Borgwardt, S., Winton-Brown, T., Nosarti, C., O' Carroll, C. M., Seal, M., Allen, P., et al. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.184 · Cited by 680
Wechsler Test of Adult Reading
(2001) · PsycTESTS Dataset · doi:10.1037/t15180-000 · Cited by 616
An event-related potential study of recognition memory with and without retrieval of source
Wilding, E. L., & Rugg, M. D. (1996) · Brain · doi:10.1093/brain/119.3.889 · Cited by 578
High-potency cannabis and the risk of psychosis
Di Forti, M., Morgan, C., Dazzan, P., Pariante, C., Mondelli, V., Marques, T. R., Handley, R., Luzi, S., Russo, M., Paparelli, A., et al. (2009) · British Journal of Psychiatry · doi:10.1192/bjp.bp.109.064220 · Cited by 567
Self-citationThe Environment and Schizophrenia: The Role of Cannabis Use
Henquet, C. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbi027 · Cited by 468
Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug
Zuardi, A. W., Crippa, J. A. S., Hallak, J. E. C., Moreira, F. A., & Guimarães, F. S. (2006) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2006000400001 · Cited by 415
Antianxiety effect of cannabidiol in the elevated plus-maze
Guimarães, F. S., Chiaretti, T. M., Graeff, F. G., & Zuardi, A. W. (1990) · Psychopharmacology · doi:10.1007/bf02244012 · Cited by 379
Curran, V. H., Brignell, C. M., Fletcher, S., Middleton, P. M., & Henry, J. A. (2002) · Psychopharmacology · doi:10.1007/s00213-002-1169-0 · Cited by 370
Cannabidiol for the treatment of psychosis in Parkinson's disease
Zuardi, A., Crippa, J., Hallak, J., Pinto, J., Chagas, M., Rodrigues, G., Dursun, S., & Tumas, V. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881108096519 · Cited by 355
Morgan, C. J. A., Schafer, G., Freeman, T. P., & Curran, H. V. (2010) · British Journal of Psychiatry · doi:10.1192/bjp.bp.110.077503 · Cited by 305
Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis
Morgan, C. J. A., & Curran, H. V. (2008) · British Journal of Psychiatry · doi:10.1192/bjp.bp.107.046649 · Cited by 300
Self-citationD’Souza, D. C., Ranganathan, M., Braley, G., Gueorguieva, R. V., Zimolo, Z., Cooper, T. B., Perry, E. B., & Krystal, J. H. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301643 · Cited by 271
Leweke, F. M., Giuffrida, A., Koethe, D., Schreiber, D., Nolden, B. M., Kranaster, L., Neatby, M. A., Schneider, M., Gerth, C. W., Hellmich, M., et al. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.04.025 · Cited by 240
Karschner, E. L., Darwin, W. D., Goodwin, R. S., Wright, S., & Huestis, M. A. (2010) · Clinical Chemistry · doi:10.1373/clinchem.2010.152439 · Cited by 231
Ren, Y., Whittard, J., Higuera-Matas, A., Morris, C. V., & Hurd, Y. L. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.4291-09.2009 · Cited by 210
Wolf, S. A., Bick-Sander, A., Fabel, K., Leal-Galicia, P., Tauber, S., Ramirez-Rodriguez, G., Müller, A., Melnik, A., Waltinger, T. P., Ullrich, O., et al. (2010) · Cell Communication and Signaling · doi:10.1186/1478-811x-8-12 · Cited by 208
Morgan, C. J., Freeman, T. P., Schafer, G. L., & Curran, H. V. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.58 · Cited by 196 · cited 4×
“In contrast, we recently found in a naturalistic study that CBD in smoked cannabis did not mediate acute psychotic symptoms in cannabis users (Morgan et al. 2010a).”
BackgroundResultInfluentialInteractive effects of subanesthetic ketamine and subhypnotic lorazepam in humans
Krystal, J. H., Karper, L. P., Bennett, A., D’Souza, D. C., Abi‐Dargham, A., Morrissey, K., Abi‐Saab, D., Bremner, J. D., Bowers, M. B., Suckow, R. F., et al. (1998) · Psychopharmacology · doi:10.1007/s002130050503 · Cited by 184
Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis
Koethe, D., Giuffrida, A., Schreiber, D., Hellmich, M., Schultze‐Lutter, F., Ruhrmann, S., Klosterkötter, J., Piomelli, D., & Leweke, F. M. (2009) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.108.053843 · Cited by 178
Demirakca, T., Sartorius, A., Ende, G., Meyer, N., Welzel, H., Skopp, G., Mann, K., & Hermann, D. (2010) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2010.09.020 · Cited by 162
Acute and Non-acute Effects of Cannabis on Brain Functioning and Neuropsychological Performance
González, R. (2007) · Neuropsychology Review · doi:10.1007/s11065-007-9036-8 · Cited by 140
Hermann, D., Sartorius, A., Welzel, H., Walter, S., Skopp, G., Ende, G., & Mann, K. F. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.08.027 · Cited by 135
Effects of long-term cannabis use on selective attention: An event-related potential study
Solowij, N., Michie, P. T., & Fox, A. M. (1991) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(91)90382-c · Cited by 124
Morphometric studies of the rat hippocampus following chronic delta-9-tetrahydrocannabinol (THC)
Scallet, A. C., Uemura, E., Andrews, A. M., Ali, S. F., McMillan, D. E., Paule, M. G., Brown, R. M., & Slikker, W. (1987) · Brain Research · doi:10.1016/0006-8993(87)91576-9 · Cited by 122
Cannabis use and psychiatric and cogitive disorders: the chicken or the egg?
di Forti, M., Morrison, P., Butt, A., & Murray, R. (2007) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e3280fa838e · Cited by 120
Acute cannabis use causes increased psychotomimetic experiences in individuals prone to psychosis
Mason, O. J., Morgan, C. J. A., Dhiman, S. K., Patel, A., Parti, N., Patel, A., & Curran, H. V. (2008) · Psychological Medicine · doi:10.1017/s0033291708004741 · Cited by 71
Research works printed but not linked: 3
- Spielberger, 1983, State-Trait Anxiety Inventory (Form Ys)
- Hardwick, 2008, Home Office Cannabis Potency Study
- 2009, World Drug Report 2009
Cited by
Sorted by citations
Acute and Chronic Effects of Cannabinoids on Human Cognition—A Systematic Review
Broyd, S. J., van Hell, H. H., Beale, C., Yücel, M., & Solowij, N. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.12.002 · Cited by 674
Cannabis, a complex plant: different compounds and different effects on individuals
Atakan, Z. (2012) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125312457586 · Cited by 612
Campos, A. C., Moreira, F. A., Gomes, F. V., Del Bel, E. A., & Guimarães, F. S. (2012) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2011.0389 · Cited by 475
Association Between Cannabis and Psychosis: Epidemiologic Evidence
Gage, S. H., Hickman, M., & Zammit, S. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.08.001 · Cited by 379
Keep off the grass? Cannabis, cognition and addiction
Curran, H. V., Freeman, T. P., Mokrysz, C., Lewis, D. A., Morgan, C. J. A., & Parsons, L. H. (2016) · Nature reviews. Neuroscience · doi:10.1038/nrn.2016.28 · Cited by 389
Metadata
- Authors
- Morgan, C. J. A., Gardener, C., Schafer, G., Swan, S., Demarchi, C., Freeman, T. P., Warrington, P., Rupasinghe, I., Ramoutar, A., Tan, N., Wingham, G., Lewis, S., & Curran, H. V.
- Affiliations
- University College London (GB)
- Corresponding author
- Morgan, C. J. A.
- Venue
- Psychological Medicine
- Publisher
- Cambridge University Press (CUP)
- Published
- 2011-07-29
- Volume
- 42
- Issue
- 2
- Pages
- 391-400
- ISSN
- 0033-2917 (ISSN-L)
- 1469-8978
- OpenAlex
- W2108405197
- Cited by
- 195
- References
- 36
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 5 · 2023: 13 · 2022: 14 · 2021: 21 · 2020: 20 · 2019: 17 · 2018: 16 · 2017: 18 · 2016: 14 · 2015: 19 · 2014: 9 · 2013: 11 · 2012: 8
- FWCI
- 6.56
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Psychological Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Bank (Australian Catholic University) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Research Portal (King's College London) (submittedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- Funders
- Medical Research Council
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- cannabinoids, cannabidiol, delta-9-tetrahydrocannabinol, psychotic-like symptoms, memory impairment, source memory, prose recall, depression, anxiety, psychological well-being, hair analysis
- MeSH terms
- Adolescent, Adult, Anxiety, Cannabidiol, Cognition Disorders, Depression, Female, Hair, Humans, Male, Marijuana Smoking, Memory, Psychoses, Substance-Induced, Schizotypal Personality Disorder, Illicit Drugs, Dronabinol, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
